168 related articles for article (PubMed ID: 38142436)
1. Whole-genome CRISPR screening identifies molecular mechanisms of PD-L1 expression in adult T-cell leukemia/lymphoma.
Chiba M; Shimono J; Suto K; Ishio T; Endo T; Goto H; Hasegawa H; Maeda M; Teshima T; Yang Y; Nakagawa M
Blood; 2024 Apr; 143(14):1379-1390. PubMed ID: 38142436
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia/lymphoma.
Miyoshi H; Kiyasu J; Kato T; Yoshida N; Shimono J; Yokoyama S; Taniguchi H; Sasaki Y; Kurita D; Kawamoto K; Kato K; Imaizumi Y; Seto M; Ohshima K
Blood; 2016 Sep; 128(10):1374-81. PubMed ID: 27418641
[TBL] [Abstract][Full Text] [Related]
3. Neddylation inhibition upregulates PD-L1 expression and enhances the efficacy of immune checkpoint blockade in glioblastoma.
Zhou S; Zhao X; Yang Z; Yang R; Chen C; Zhao K; Wang W; Ma Y; Zhang Q; Wang X
Int J Cancer; 2019 Aug; 145(3):763-774. PubMed ID: 31044422
[TBL] [Abstract][Full Text] [Related]
4. PD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients.
Kozako T; Yoshimitsu M; Fujiwara H; Masamoto I; Horai S; White Y; Akimoto M; Suzuki S; Matsushita K; Uozumi K; Tei C; Arima N
Leukemia; 2009 Feb; 23(2):375-82. PubMed ID: 18830259
[TBL] [Abstract][Full Text] [Related]
5. Genome-wide CRISPR screens identify CD48 defining susceptibility to NK cytotoxicity in peripheral T-cell lymphomas.
Chiba M; Shimono J; Ishio T; Takei N; Kasahara K; Ogasawara R; Ara T; Goto H; Izumiyama K; Otsuguro S; Perera LP; Hasegawa H; Maeda M; Hashino S; Maenaka K; Teshima T; Waldmann TA; Yang Y; Nakagawa M
Blood; 2022 Nov; 140(18):1951-1963. PubMed ID: 35921533
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive immunohistochemical analysis of immune checkpoint molecules in adult T cell leukemia/lymphoma.
Takeuchi M; Miyoshi H; Nakashima K; Kawamoto K; Yamada K; Yanagida E; Muta H; Moritsubo M; Umeno T; Suzuki T; Seto M; Ohshima K
Ann Hematol; 2020 May; 99(5):1093-1098. PubMed ID: 32157421
[TBL] [Abstract][Full Text] [Related]
7. Targeting PD-L1 to treat ATLL?
Marçais A
Blood; 2024 Apr; 143(14):1320-1322. PubMed ID: 38573604
[No Abstract] [Full Text] [Related]
8. PD-1 and PD-L1 inhibitors foster the progression of adult T-cell Leukemia/Lymphoma.
Jalili-Nik M; Soltani A; Mashkani B; Rafatpanah H; Hashemy SI
Int Immunopharmacol; 2021 Sep; 98():107870. PubMed ID: 34153661
[TBL] [Abstract][Full Text] [Related]
9. Expression pattern of immunosurveillance-related antigen in adult T cell leukaemia/lymphoma.
Asano N; Miyoshi H; Kato T; Shimono J; Yoshida N; Kurita D; Sasaki Y; Kawamoto K; Ohshima K; Seto M
Histopathology; 2018 May; 72(6):945-954. PubMed ID: 29297942
[TBL] [Abstract][Full Text] [Related]
10. Prognostic implication of CTLA-4, PD-1, and PD-L1 expression in aggressive adult T-cell leukemia-lymphoma.
Onishi A; Fuji S; Kitano S; Maeshima AM; Tajima K; Yamaguchi J; Kawashima I; Kawajiri A; Takemura T; Ito A; Tanaka T; Okinaka K; Inamoto Y; Kurosawa S; Kim SW; Munakata W; Maruyama D; Tobinai K; Fukuda T
Ann Hematol; 2022 Apr; 101(4):799-810. PubMed ID: 35032188
[TBL] [Abstract][Full Text] [Related]
11. An IL-27/Stat3 axis induces expression of programmed cell death 1 ligands (PD-L1/2) on infiltrating macrophages in lymphoma.
Horlad H; Ma C; Yano H; Pan C; Ohnishi K; Fujiwara Y; Endo S; Kikukawa Y; Okuno Y; Matsuoka M; Takeya M; Komohara Y
Cancer Sci; 2016 Nov; 107(11):1696-1704. PubMed ID: 27564404
[TBL] [Abstract][Full Text] [Related]
12. Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in adult T-cell leukemia/lymphoma.
Ishio T; Kumar S; Shimono J; Daenthanasanmak A; Dubois S; Lin Y; Bryant B; Petrus MN; Bachy E; Huang DW; Yang Y; Green PL; Hasegawa H; Maeda M; Goto H; Endo T; Yokota T; Hatanaka KC; Hatanaka Y; Tanaka S; Matsuno Y; Yang Y; Hashino S; Teshima T; Waldmann TA; Staudt LM; Nakagawa M
Blood; 2022 Mar; 139(10):1541-1556. PubMed ID: 34818414
[TBL] [Abstract][Full Text] [Related]
13. Potential anti-lymphoma effect of M-CSFR inhibitor in adult T-cell leukemia/lymphoma.
Komohara Y; Noyori O; Saito Y; Takeya H; Baghdadi M; Kitagawa F; Hama N; Ishikawa K; Okuno Y; Nosaka K; Seino KI; Matsuoka M; Suzu S
J Clin Exp Hematop; 2018; 58(4):152-160. PubMed ID: 30541986
[TBL] [Abstract][Full Text] [Related]
14. Programmed cell death ligand 1 disruption by clustered regularly interspaced short palindromic repeats/Cas9-genome editing promotes antitumor immunity and suppresses ovarian cancer progression.
Yahata T; Mizoguchi M; Kimura A; Orimo T; Toujima S; Kuninaka Y; Nosaka M; Ishida Y; Sasaki I; Fukuda-Ohta Y; Hemmi H; Iwahashi N; Noguchi T; Kaisho T; Kondo T; Ino K
Cancer Sci; 2019 Apr; 110(4):1279-1292. PubMed ID: 30702189
[TBL] [Abstract][Full Text] [Related]
15. A novel model of controlling PD-L1 expression in ALK
Zhang JP; Song Z; Wang HB; Lang L; Yang YZ; Xiao W; Webster DE; Wei W; Barta SK; Kadin ME; Staudt LM; Nakagawa M; Yang Y
Blood; 2019 Jul; 134(2):171-185. PubMed ID: 31151983
[TBL] [Abstract][Full Text] [Related]
16. [The microenvironment and immune status of peripheral T-cell lymphoma: focusing on AITL and ATLL].
Ohshima K; Miyoshi H; Yamada K
Rinsho Ketsueki; 2018; 59(5):574-587. PubMed ID: 29877249
[TBL] [Abstract][Full Text] [Related]
17. Development of anti-human CADM1 monoclonal antibodies as a potential therapy for adult T-cell leukemia/lymphoma.
Chilmi S; Nakahata S; Fauzi YR; Ichikawa T; Tani C; Suwanruengsri M; Yamaguchi R; Matsuura T; Kurosawa G; Morishita K
Int J Hematol; 2020 Oct; 112(4):496-503. PubMed ID: 32656636
[TBL] [Abstract][Full Text] [Related]
18. Phosphorylated STAT3 expression predicts better prognosis in smoldering type of adult T-cell leukemia/lymphoma.
Morichika K; Karube K; Kayo H; Uchino S; Nishi Y; Nakachi S; Okamoto S; Morishima S; Ohshiro K; Nakazato I; Fukushima T; Masuzaki H
Cancer Sci; 2019 Sep; 110(9):2982-2991. PubMed ID: 31237072
[TBL] [Abstract][Full Text] [Related]
19. Development of a complete human IgG monoclonal antibody to transferrin receptor 1 targeted for adult T-cell leukemia/lymphoma.
Shimosaki S; Nakahata S; Ichikawa T; Kitanaka A; Kameda T; Hidaka T; Kubuki Y; Kurosawa G; Zhang L; Sudo Y; Shimoda K; Morishita K
Biochem Biophys Res Commun; 2017 Mar; 485(1):144-151. PubMed ID: 28189691
[TBL] [Abstract][Full Text] [Related]
20. Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma.
Xie M; Huang X; Ye X; Qian W
Int Immunopharmacol; 2019 Dec; 77():105999. PubMed ID: 31704289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
